Biocytogen’s severely immune-deficient B-NDG mice are good host for engraftment of human PBMC and CD34+ hematopoietic stem cells (hHSC). These human immune cell engraftment models are powerful tools for examining effect of immuno-oncology agents on human immune cells and assessing efficacy of such test agents on CDX and PDX tumor growth.
Case 1: Anti-CDX tumore efficacy study by monoclonal and bispecific antibodies in human PBMC engrafted B-NDG mice
Efficacy study of monoclonal and bispecific antibodies in human PBMC engrafted B-NDG mice of Raji-Luc B lymphoma model.
Case 2: Anti-CDX tumore efficacy study in human CD34+ engrafted B-NDG mice
B-NDG mice engrafted with CD34+ HSC cells were used for in vivo efficacy assessment. Mice were treated with anti-human PD-1 antibody Pembrolizumab or anti-CD20 antibody Rituximab after Raji-Luc cell implantation. Dramatic tumor growth inhibition by both Pembrolizumab and Rituximab was observed.
Case 3: Anti-PDX tumor efficacy study by anti-human PD-1 antibody in human CD34+ engrafted B-NDG mice
Efficacy evaluation of the human PD-1 antibody Pembrolizumab in CD34+ HSC engrafted B-NDG mice implanted with hPD-L1 positive lung PDX.